Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis
Authors:
- 13 November 2019
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 65 (6) , 1767-1776
Abstract
Golimumab is a new anti-TNF-alpha monoclonal antibody for patients with ulcerative colitis.Keywords
This publication has 16 references indexed in Scilit:
- Interpretation and Impact of Real-World Clinical Data for the Practicing ClinicianAdvances in Therapy, 2018
- Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)BMJ Open Gastroenterology, 2018
- Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative ColitisInflammatory Bowel Diseases, 2017
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch DisordersJournal of Crohn's and Colitis, 2017
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementJournal of Crohn's and Colitis, 2017
- Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter studyWorld Journal of Gastroenterology, 2016
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2014
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2014
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?American Journal of Gastroenterology, 2011
- Golimumab as the First Monthly Subcutaneous Fully Human Anti-TNF-α Antibody in the Treatment of Inflammatory ArthropathiesImmunotherapy, 2010